EN DE
Watch Si-Bone Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Si-Bone Inc (SIBN) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Si-Bone Inc stock $17.89, price $23.41, that is 23.6% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US8257041090

SB Si-Bone Inc logo Thin data Nov 17, 2026

Si-Bone Inc

SIBN · US

Expensive (fair value 24% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Quality 48/100 
Expensive Growth (revenue 5y +22.3 %/yr in USD) 
Insiders sold $9.3M (6M) 
Fair value $17.89 · Overvalued 
Loss-making · -6.2% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch Si-Bone Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$28.90 $11.23 Fair Value $17.89 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $11.23 – $28.90 · fair‑value band $13.42 – $22.37 · the $23.41 price screens above the $17.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Si-Bone in your weekly email

Every Wednesday you see whether Si-Bone is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.

Show moreShow less

It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.

The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Stock analysis

Si-Bone Inc (SIBN) currently trades at $23.41, while our estimate is $17.89, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $13.42 (bear) to $22.37 (bull), the price of $23.41 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Si-Bone Inc reported revenue of $201M in FY2025 versus $90.2M in FY2021, a compound +22.2%/yr. Reported net income was −$18.9M in FY2025.

Key figures

Market cap $1.0B Small · P/S ratio 4.96 · EPS (TTM) $−0.3100 · Net margin −6.2% · Return on equity −7.7% · Return on assets (EBIT) −22.0% (5-year average) · Operating margin −7.8% · Revenue (TTM) $221M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 102% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −24%, SIBN screens richer than that median.

Fair Value

Bear $13.42 Fair Value $17.89 Bull $22.37
Price $23.41 · Downside -23.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 32
How much profit the company makes from its sales and capital
Quality Growth 88
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 38
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 77
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 79
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $9.3M and none bought.

  • SaleMichael A. PisetskySVP, Ops & Adm/Chief Legal Ofr12× since Nov 17, 2025: 130,302 shares, avg. $20.56$2.7MNov 4, 2026
  • SaleLaura FrancisChief Executive Officer, Director8× since Nov 17, 2025: 334,925 shares, avg. $19.39$6.5MNov 4, 2026
  • SaleAnshul MaheshwariChief Op & Financial Officer14× since Nov 17, 2025: 106,670 shares, avg. $18.54$2.0MNov 4, 2026
  • SaleJeffrey W DunnDirector9× since Dec 8, 2025: 124,249 shares, avg. $19.41$2.4MNov 2, 2026
  • SaleTimothy E Davis JRDirector7,280 shares at $14.31$104,187May 29, 2026
  • SaleMika NishimuraDirector4,100 shares at $13.83$56,703Mar 12, 2026
  • SaleAnthony J RecuperoOther3× since Nov 17, 2025: 28,559 shares, avg. $16.22$463,239Feb 17, 2026

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.3%
Start year 2020 (pandemic). Over 10 years: +17.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.6% (2020) → −11.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SIBN screens overvalued: fair value 24% below the price. Compare with Abbott Laboratories, →

Compare Si-Bone Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −23.6% · Below median
Profitability
Return on assets −7.9% · Below median
Net margin (12 months) −6.2% · Below median
Operating margin (12 months) −7.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 14.5% · Above median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 5.83× · Priciest 25%
P/S (12 months) 4.69× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 17
FUTURE (revenue growth)73 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)90 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs SIBN
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs SIBN
Stryker Corporation SYK $310.72 $340.60 +10% vs SIBN
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs SIBN
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs SIBN
Siemens Healthineers AG SHL €44.00 €34.51 −22% vs SIBN
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs SIBN
Medtronic plc MDT $102.88 $74.89 −27% vs SIBN
Abbott Laboratories, ABT $107.45 $75.28 −30% vs SIBN
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs SIBN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Si-Bone Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Si-Bone Inc Fair Value". https://www.fairvalue-calculator.com/stock/SIBN

Frequently asked questions

Is Si-Bone Inc (SIBN) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $17.89 versus a price of $23.41, about 24% lower (overvalued).
What is the fair value of SIBN?
Our estimate for Si-Bone Inc is $17.89 (as of Nov 17, 2026), built from audited fundamentals. The current price: $23.41.
What is the quality score of SIBN?
Si-Bone Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Si-Bone Inc (SIBN)?
Our calculated price target is the estimate of $17.89 (as of Nov 17, 2026). Cautious scenario $13.42, optimistic scenario $22.37. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Si-Bone Inc stock forecast for 2026?
Our estimate puts fair value at $17.89, about 24% lower versus a price of $23.41 (overvalued). Cautious scenario $13.42, optimistic scenario $22.37. The calculation is refreshed regularly with new filings.
What is the revenue of Si-Bone Inc (SIBN)?
Si-Bone Inc reported trailing-twelve-month revenue of about $221M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Si-Bone Inc (SIBN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Si-Bone Inc it is $17.89 per share (as of Nov 17, 2026), against a price of $23.41.
Is Si-Bone Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SIBN trades above its calculated fair value: price $23.41, fair value $17.89, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SIBN?
No. The price is what the market pays today ($23.41); the fair value is what the company's own numbers justify ($17.89). For Si-Bone Inc the two are $5.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is Si-Bone Inc worth?
The market values Si-Bone Inc at about $1.0B (market capitalisation, as of Nov 17, 2026). Per share that is $23.41; our models calculate a fair value of $17.89 per share.
What do the bullish and bearish scenarios say about SIBN?
Our models span a range for Si-Bone Inc: cautious scenario $13.42, base $17.89, optimistic $22.37 per share (as of Nov 17, 2026, price $23.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Si-Bone Inc (SIBN)?
Balance-sheet figures for Si-Bone Inc (as of Nov 17, 2026): return on equity −7.7%, debt of 0.20 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is SIBN from its 52-week high?
Si-Bone Inc trades at $23.41, about 9% below its 52-week high of $25.60 and 102% above the low of $11.61 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $17.89 is for.
Which stocks are comparable to Si-Bone Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Si-Bone Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $23.41, calculated fair value $17.89 (−24%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Si-Bone Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Si-Bone Inc (SIBN)?
The closing price on Nov 16, 2026 was $23.41. Our estimate is $17.89, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Si-Bone Inc right now?
The price sits above even our optimistic bull case ($22.37). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Si-Bone Inc

How large is the market capitalisation of Si-Bone Inc (SIBN)?
The market capitalisation of Si-Bone Inc is $1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Si-Bone Inc (SIBN)?
The price-to-sales ratio of Si-Bone Inc is 4.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Si-Bone Inc (SIBN)?
Earnings per share at Si-Bone Inc are $−0.3100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Si-Bone Inc (SIBN)?
The net margin of Si-Bone Inc is −6.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Si-Bone Inc (SIBN)?
The return on equity (ROE) of Si-Bone Inc is −7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Si-Bone Inc (SIBN)?
On an EBIT basis the return on assets of Si-Bone Inc is −22.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Si-Bone Inc (SIBN)?
The operating margin of Si-Bone Inc is −7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Si-Bone Inc (SIBN)?
Revenue at Si-Bone Inc is growing 14.5% versus a year earlier (3y avg +23.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Si-Bone Inc (SIBN) generate?
The free cash flow of Si-Bone Inc is −$9.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Si-Bone Inc (SIBN) hold?
Si-Bone Inc holds more cash than debt, $41.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Si-Bone Inc in the live analysis

One click puts Si-Bone Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.